Where Moderna Stands With Analysts

Recent analyst ratings for Moderna (MRNA) show a downward trend in price targets, with the average 12-month target decreasing by 16.94% to $37.62. Over the last three months, analyst sentiment has shifted towards a more bearish outlook, reflected in several firms lowering their price targets and ratings, citing concerns over revenue decline (-35.93% as of March 31, 2025) and weak profitability metrics like net margin (-907.48%). Despite a relatively healthy debt-to-equity ratio, Moderna's financial performance lags behind industry averages, contributing to the negative revisions.

Analysis

Analyst sentiment surrounding Moderna (NASDAQ:MRNA) has demonstrably soured over the past three months, with a notable shift towards more cautious or bearish outlooks. This is underscored by a 16.94% decrease in the average 12-month price target to $37.62, down from a prior average of $45.29. Specific actions from prominent firms such as JP Morgan, UBS, Barclays, RBC Capital, Evercore ISI Group, and Morgan Stanley reflect this trend, with all listed analysts lowering their price targets. For instance, JP Morgan reiterated an 'Underweight' rating, reducing its target to $26.00, while UBS, despite maintaining a 'Buy' rating, lowered its target from $78.00 to $70.00. This negative revisionism appears to be driven by Moderna's challenging financial performance. The company reported a significant revenue decline of approximately -35.93% as of March 31, 2025, and its profitability metrics are severely lagging industry averages, highlighted by a net margin of -907.48%. Furthermore, Moderna's Return on Equity (ROE) at -9.26% and Return on Assets (ROA) at -7.23% also indicate difficulties in generating returns from its equity and assets effectively. While the company maintains a healthy debt-to-equity ratio of 0.07, suggesting lower reliance on debt financing, this positive aspect is overshadowed by the substantial underperformance in revenue growth and profitability compared to its Health Care sector peers. The provided sentiment score of -0.75 (strongly negative) and MRNA-specific sentiment of -0.85 corroborate this bleak near-term outlook.

Key Decisions for Investors

• Investors should critically review their positions in Moderna, considering the consistent downward revisions in analyst price targets and predominantly bearish to indifferent ratings.